Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$65.34 USD
+0.54 (0.83%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $65.32 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 301 - 304 ( 304 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiates CK-357 Peripheral Artery Disease and Claudication Phase IIa Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings and Update to CK-357 Studies and omecamtiv mecarbil Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CYTK Announces Statistically Significant Results from the CK-20173537 Phase I Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G